Drug Profile
Brachyury peptide vaccine - Bristol Myers Squibb/ImmunityBio
Alternative Names: GI-6301; Yeast brachyury vaccine - ImmunityBioLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GlobeImmune
- Developer GlobeImmune; ImmunityBio; National Cancer Institute (USA)
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Chordoma
- Phase I/II Colorectal cancer; Pancreatic cancer; Triple negative breast cancer
- No development reported Solid tumours
Most Recent Events
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio
- 18 Sep 2020 Phase I/II trial for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) is still underway in USA (NCT03563157)
- 29 May 2020 Efficacy and adverse events data from a phase II trial in Chordoma presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)